EMMA (Emmaus Life Sciences) EBITDA Margin %: -60.04% (As of Mar. 2026)


What is Emmaus Life Sciences EBITDA Margin %?

Emmaus Life Sciences EMMA -16.67% EBITDA Margin % is -60.04% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 945 Biotechnology companies, Emmaus Life Sciences ranks better than 65.4% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Emmaus Life Sciences's EBITDA for the three months ended in Mar. 2026 was $-1.19 Mil. Emmaus Life Sciences's Revenue for the three months ended in Mar. 2026 was $1.98 Mil. Therefore, Emmaus Life Sciences's EBITDA margin for the quarter that ended in Mar. 2026 was -60.04%.

Emmaus Life Sciences  (OTCPK:EMMA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Emmaus Life Sciences EBITDA Margin % Related Terms

Emmaus Life Sciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences EBITDA Margin % Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -61.92 -29.90 12.24 -5.46 -2.49

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.26 -1.53 13.29 9.06 -60.04

EMMA vs CERO, AGTX, WINT: EBITDA Margin % Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's EBITDA Margin % falls into.


Emmaus Life Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Emmaus Life Sciences's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.31/12.453
=-2.49 %

Emmaus Life Sciences's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.19/1.982
=-60.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -60.04% mean?
Emmaus Life Sciences (EMMA) has a EBITDA Margin % of -60.04% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #327 out of 945 companies in the Biotechnology industry, placing it in the top 34.6%.
Is Emmaus Life Sciences' EBITDA Margin % too high?
Emmaus Life Sciences' current EBITDA Margin % is -60.04%. Based on the distribution chart, Emmaus Life Sciences ranks #327 out of 945 companies in the Biotechnology industry, which is above the industry midpoint.
How does Emmaus Life Sciences' EBITDA Margin % compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #327 out of 945 companies for EBITDA Margin %. This puts Emmaus Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current EBITDA Margin % is -60.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current EBITDA Margin % is -60.04%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current EBITDA Margin % is -60.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.